JLL Partners Inc., a New York-based private-equity firm, agreed to buy a majority stake in vitamin- maker Royal DSM NV’s pharmaceuticals business to create a new company in a deal valued at $2.6 billion.

The unit will be rolled into Patheon Inc., a Canada-based specialty-pharmaceuticals manufacturer controlled by JLL, the companies said in a joint statement today. The new entity is projected to have sales next year of about $2 billion. DSM shares gained as much as 3.7 percent in Amsterdam trading.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.